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Immunotherapy1. Introduction
Recent advances in the use of immunotherapy for the
treatment of cancers have led to the development of reliable
methods for the large-scale expansion of human CD8+ T
lymphocytes (Gattinoni et al., 2006; Zhang et al., 2014). Such
studies are often preceded by “proof of principle” studies in
mice. However there is a lack of reliablemethods for expanding
large numbers of mouse CD8+ T cells. Here we report a
method for the reproducible, large-scale expansion of mouse
CD8+ T cells of high viability and their use in transfection and
in vivo tracking experiments.ar and Experimental
ardiff CF14 4XN, UK.
.V. This is an open access artic2. Material and methods
2.1. Mice
Non-obese diabetic (NOD) and C57BL/6micewere used. All
procedures were performed in accordance with the protocols
approved by the UK Home Office.
2.2. CD8+ T cell isolation
CD8+ T cells were isolated from the spleens under aseptic
conditions. Individual spleens were homogenized to release
splenocytes, in 5 ml RPMI 1640 medium. The cell suspension
was centrifuged (5 min at 400 g at room temperature), the
supernatant decanted and the cells resuspended in the residual
volume (approximately 100 μl). Erythrocytes were lysed briefly
in 900 μl sterile water (1–2 s) before the addition of 100 μl 10×
PBS to restore iso-osmolarity and 5 ml serum-free RPMI 1640
medium. The single-cell suspensions from individual spleens
were pooled, filtered through a 40 μm cell strainer (Fisher) and
counted. CD8+ T cells were isolated usingmagnetic cell sortingle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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according to the manufacturer's instructions. Cell samples were
taken prior and post-magnetic selection followed by staining
with a fixable viability dye (eFluor 506, eBiosciences), anti-CD8-
APC (clone 53-6.7, BioLegend), anti-CD4-FITC (clone GK1.5, BD
Pharmingen), and anti-CD19-PerCPCy5.5 (clone 1D3, BD
Pharmingen) to check sample purity.
2.3. Cell culture
T cells were initially plated into 6-well plates (Nunc, Thermo
Fisher Scientific) coated with anti-CD3 (clone 2C11, Bio X Cell)
and anti-CD28 (clone 37.51, Bio X Cell). The plates were coated
with 0.5 μg/ml anti-CD3 and 5 μg/ml anti-CD28 in PBS (5 ml/
well) overnight at 4 °C and washed twice with PBS prior to
plating cells. The CD8+T cellswere plated (day 0) at 5 × 106 per
well in RPMI medium (PAA Laboratories) containing 10% heat-
inactivated fetal bovine serum (Sigma) and supplemented to a
final concentration with L-glutamine (2 mM), penicillin (50 U/
ml), streptomycin (50 μg/ml), 2-mercaptoethanol (50 μM), 1%
ITS: insulin (1.7 μM), transferrin (68.8 μM) and sodium selenite
(3.9 nM), all from Life Technologies. The cells were cultured for
24 h (37 °C, 5% CO2, day 1), after which IL-7 (recombinant
mouse, R&DSystems) and IL-2 (EL-4 culture supernatant,Wong
et al., 1996) were added to final concentrations of 0.5 ng/ml and
30 U/ml respectively. The cells were then cultured for a further
24 h (day 2). At this point, the cells were harvested from the
wells by resuspending them in the medium using a plastic
Pasteur pipette and subcultured by plating at 1 × 106/well into a
6-well plate, freshmedium containing all supplements including
IL-7 and IL-2 being added to a final volumeof 5 ml/well. The cells
were cultured for a further 24 h (day 3), harvested and re-plated
at 1 × 106/well as for day 2 and cultured for a further 24 h. Cells
were harvested on day 4 for transfection.
2.4. Transfection and cell transfer
A GFP construct (GFP in pGEM4Z/GFP/A64 vector;
Boczkowski et al., 2000) was used as template DNA for
in vitro transcription of RNA. mRNA was synthesized from
this DNA template with a T7 mScript Standard mRNA
Production System (CellScript, Madison, WI, USA; Perez et al.,
2014). CD8+ T cells were harvested, pooled and pelleted by
centrifugation (400 g for 5 min). The cells were then washed
twice with 20 ml Opti-MEM (Life Technologies) by resuspen-
sion and centrifugation, before being resuspended in cold Opti-
MEM at 10 × 106/200 μl and kept on ice. The cells (10 × 106)
were transfectedwith 5 μg GFPmRNA, by electroporation (BTX
Harvard Apparatus ECM830) at 300 V for 1 ms in a precooled
2mmcuvette (BTX). After transfection, the cells were added toTable 1
Expansion of CD8+ T cells in RPMI 1640 medium with different supplements.
Results were compared by analysis of variance (ANOVA) with subsequent comparison
Medium Fold expansion after 4 days
(mean n = 4)
Standard err
RPMI + 5% FCS 5.1 0.95
RPMI + 5% FCS + ITS 16.7 3.8
RPMI 10% FCS 13 1.5
RPMI 10% FCS + ITS 20 1.2complete medium containing IL2 and IL7 (b2 × 106 cells/ml)
and rested for 3 h at room temperaturewith periodicmixing to
prevent the cells frompelleting. The cellswerewashed twice in
PBS and resuspended at 5 × 107 cells/ml in normal saline. As a
control, CD8+ T cells were subjected to the electroporation
procedure but with no added mRNA (mock transfection).
Transfected cells (GFP and mock transfected) were adoptively
transferred into 6-week old NOD mice recipients by injection
into the tail vein (10 × 106 cells per mouse). Lymphoid tissues
(spleen and pancreatic lymph nodes) were harvested after 1, 3
and 7 days. GFP positive cells were identified by flow
cytometry.
2.5. Flow cytometry
Cells (1 × 106 per tube) were stained with anti-CD8-PECy7
(clone YTS156.7.7, BioLegend), and with a viability dye
(eFluor 506, eBioscience) for studies testing GFP expression.
Cells (1 × 106) were stained for cell surface antigens using the
following antibody panels: panel 1, anti-CD8-APC (clone 53-6.7,
BioLegend), anti-CD103-FITC (clone 2E7, eBioscience), anti-LFA-
1/CD11a-PE-Cy7 (clone M17/4, eBioscience), anti-CD25-PE
(clone PC61, BioLegend) and with a viability dye (eFluor 780,
eBioscience); panel 2, anti-CD8-FITC (clone 53-6.7, BD Biosci-
ence), anti-CTLA-4-Brilliant Violet 421 (clone UC10-4B9,
BioLegend), anti-CD127/IL-7Rα-PE (clone SB/199, BD Biosci-
ence), anti-KLRG1-APC (clone 2F1/KLRG1, BioLegend), anti-
CD69-PECy7 (clone H1.2F3, BioLegend) and with a viability
dye (eFluor 780, eBioscience); and panel 3, anti-CD8-APC (clone
53-6.7 BioLegend) and anti-CD215/IL-15Rα-PE (clone DNT15Ra,
eBioscience). Samples for intracellular cytokine staining were
treated with monensin (2 μM), PMA (80 nM) and ionomycin
(0.8 μM) for 3hprior to staining. Cells (1×106per tube)were first
stained with anti-CD8-FITC (clone 53-6.7, BD Bioscience) and a
viability dye (eFluor 506, eBioscience). Following surface marker
staining cells were fixed and permeabilized (BD Bioscience,
CytoFix/CytoPerm Buffer) and then stained with anti-IL-10-
PerCP Cy5.5 (clone JESS-16E3, eBioscience), anti-interferon
gamma-APC (clone XMG1.2, BD Bioscience) and anti-TNFα-PE
(clone MP6-XT22, BD Bioscience). Samples were run on a
FacsCanto II (BD) flow cytometer and data were analyzed using
FlowJo software (Tree Star). Isotype controls were run for
intracellular cytokine staining.
3. Results
Negative selection of CD8+ cells gave a 91% pure
population of CD8+ cells (89%–95.6%, n = 5) with CD4
contamination of 0.21% (0.1%–0.49%, n = 5), B cell contamina-
tion of 1.58% (0.38%–3%, n= 5) and very high viability (N99%).s by Student–Newman–Keuls Multiple comparison test.
or Signiﬁcance compared to RPMI
+ 5% FCS
Viability of cells after
expansion
NA 83.5%
p b 0.01 94.8%
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Fig. 1. CD8+ T cell expansion with different growth media supplements.
Growth rates of CD8+ T cells in RPMImediumwith either 5 or 10% FCS and ITS
(+). Cell expansion is defined as fold changewith respect to day 0,where day 0
is defined as 1. The timings of the addition of cytokines and sub-culture are also
indicated. The results are the mean of 4 separate experiments ± SE.
Table 2
Markers of T-cell activation in expanded and control cells.
Expanded and control cells were stained for markers of T-cell activation and
analyzed by ﬂow cytometry. Results are expressed as the percentage of live
CD8+ cells that are positive for that marker.
% positive cells
Marker Expanded cells Control cells
CD103 4.7 11.3
CD25 99.6 2.5
LFA-1/CD11a 98.4 31
KLRG1 0 4.5
CTLA-4 13.6 1
CD69 2.1 5.2
CD127/IL-7R 21.2 5
CD215/IL-15Rα 41.1 3.8
Interferon-γ 87.9 14.3
TNF-α 74.2 33.2
IL-10 0 0
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protocol described above was improved by increasing the FCS
concentration from 5% to 10% and improved further by
supplementing the medium with ITS. These comparisons are
shown in Table 1 and Fig. 1.
The combination of increasing the FCS to 10% and including
ITS in the medium significantly increased the expansion
compared to RPMI 5% without ITS (20 fold CD8+ T cell
expansion±1.2 compared to 5.1 fold CD8+T cell expansion±
0.95, p b 0.01, n = 4). The addition of ITS to RPMI 5% increased
expansion (16.7±3.8, p b 0.01), as did increasing the FCS to 10%
without ITS (13± 1.5, p b 0.05) but to a lesser extent than RPMI
10% + ITS. The viability of the cells in all three was increased
compared to RPMI 5% (Fig. 1).
In order to look at the effect of the expansion/activation
process on the cells, they were stained with markers of T cell
activation. Non-expanded NOD spleen cells were also stained
as a control. The results are expressed as the percentage of live
CD8+ cells that are positive for each marker and are shown in
Table 2. As expected, CD25, LFA1, CTLA4, IL-7R and IL-15Rwere
upregulated on the cells and they considerably increased the
proportion of IFN-γ and TNF-α producing cells, but IL-10 was
not stimulated. As the cells were examined after 4 days of
expansion, CD69 was not raised, in keeping with the time
course of increase, as it peaks within the first 24–48 h, and
KLRG1, a marker of memory cells was not upregulated as the
time course was too short for memory generation.
Transfection efficiency of the expanded NOD CD8+ cells
was assessed by flow cytometry following transfection with a
GFP- expressing mRNA construct by electroporation. Six hoursTable 3
Detection of transfected cells in spleen and PLN.
GFP- positive CD8+ T cells (% total CD8+) at 1, 3 and 7 days in spleen and
pancreatic lymph node (PLN) of mice which received 107 GFP-transfected cells
on day 0. The background ﬂuorescence from transfer of mock-transfected cells
has been subtracted.
GFP positive CD8+ T cells (% total CD8+)
Day 1 Day 3 Day 7
GFP spleen 6.4 15.11 2.52
GFP PLN 0.32 5.7 1.17after transfection, N95% of live cells were GFP positive and after
3 days in culture, N92% of live cells were still GFP positive as
assessed by flow cytometry. This confirmed that this method is
able to transfect the cells with high efficiency and that
expression of the encoded protein, is rapid and sustained for a
period of at least 3 days in vitro.
In order to test the suitability of the expanded CD8+ T cells
for immunotherapy studies following a transfection procedure,
the cells were transfected with the mRNA GFP construct,
intravenously injected into NOD mice and lymphoid tissues
harvested over a time course. The viability of transfected cells
was assessed immediately prior to transfer and routinely found
to be in excess of 90%, with no difference between mock or
GFP- transfected cells. GFP-positive CD8+ T cells were
detected at 1, 3 and 7 days after injection (Table 3 and Fig. 2),
confirming that the cells express the construct and are capable
of surviving for up to 7 days in vivo.
GFP-positive cells were detected in the spleen and PLN of
the mice that received GFP transfected cells. At day 1, GFP-
positive cells were only detected in the spleen but by day 3,
GFP-positive cells could be detected in spleen and PLN, the
greatest number being in the spleen (15.45% of total CD8+
cells). At day 7, GFP- positive cells were still detectable in both
lymphoid tissues. No GFP- positive cells were detected in mice
injected with mock transfected cells.
The suitability of the method described here for the
expansion and transfection of mouse strains other than NOD
mice was determined using C57Bl/6 mice. Spleen CD8+ cells
from C57Bl/6 mice expanded very well, with a 41-fold
expansion compared to 18-fold expansion for NOD- derived
CD8+ T cells in a parallel experiment. Additionally the
expanded C57Bl/6 CD8+ cells transfected with an efficiency
comparable to expanded NOD T cells as assessed by GFP
expression (90.1% GFP positive for C57Bl/6 compared to 91.7%
for NOD CD8+ T cells) in a parallel experiment.
4. Discussion
Previous methods for expansion of CD8+ T-cells have used
Concanavalin A (Palacios, 1982) and anti-CD3/CD28 beads
(Kalamasz et al., 2004); however these methods did not prove
reliable for the expansion of murine CD8+ cells of sufficient
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Fig. 2. Time course of detection of GFP- transfected cells in spleen and pancreatic lymph node. Flow cytometric plots illustrating gated CD8+ T cells, with percentages
indicating GFP-positive CD8+ T cells. These cells were detected in both spleen and pancreatic lymph nodes (PLN) 7 days after adoptive transfer of the transfected cells.
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our laboratory. We therefore developed a simple method for
the ex vivo expansion of CD8+T cells derived fromNODmouse
spleens, activated non-specifically and then supported by
cytokines and media supplements summarized in Fig. 1. The
cells were initially cultured in plates coated with anti-CD3 and
anti-CD28 which result in non-specific stimulation of the T cell
receptor and the CD28 co-stimulator for 48 h (supplemented
with IL-2 and IL-7 after 24 h), after which they were removed
from these plates and sub-cultured in non-coated tissue culture
plates in the presence of IL‐2 and IL‐7. When cultured in RPMI
1640 medium containing 10% FCS and supplemented with ITS,
this protocol results in a 20-fold expansion of cell number
compared to the starting cell number. Supplementing the
mediumwith ITS (insulin, transferrin and selenium) resulted in
a significant improvement in expansion. Activation of CD8+ T-
cells results in up-regulation of both insulin and IGF-II
receptors (Stentz and Kitabchi, 2004). Thus, it is possible that
the effect of ITS is due to the high levels of insulin in the ITS
(1.7 μM) with insulin acting through the insulin receptor to
promote the metabolic changes that occur during T-cell
activation, and also causing activation of the IGF-II receptor to
promote cell survival (Heaton et al., 1984).Wehave also shown
excellent expansion and high efficiency transfection of C57Bl/6
mouse CD8+ cells indicating that this method is generally
applicable to mouse CD8+ cells and not specific to cells
derived from the NOD mouse.
The activation of the CD8+T cells, as shown by upregulation
of activation markers and effective expansion of CD8+ T cells
allowed in vivo tracking in a way that significantly reduced the
number of mice used in our research, in keeping with the
principle to reduce mouse numbers by refining experimental
techniques. Typically, for each experiment where 107 cells were
needed for transfer, one donor mouse was required for 8–10recipient mice. Prior to development of the method reported
here, our studies required one donor mouse for each recipient
mouse.
In conclusion we have developed a simple and reliable
method for large-scale expansion of CD8+ T-cells, which
can subsequently be used for transfection and immunother-
apy studies.
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